SciDEX — LIRAGLUTIDE

Understanding Entity Pages

This page aggregates everything SciDEX knows about LIRAGLUTIDE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

Outgoing (41)

Target	Relation	Type	Str
BDNF	causes	gene	0.70
ATORVASTATIN	inhibits	drug	0.70
AMYLOID	causes	protein	0.70
CREB	activates	gene	0.70
CXCL10	inhibits	gene	0.65
NRF2	activates	gene	0.65
NRF2	inhibits	gene	0.65
NRF2	treats	gene	0.65
ROS	activates	phenotype	0.65
OXIDATIVE STRESS	inhibits	phenotype	0.65
OXIDATIVE STRESS	activates	phenotype	0.65
MAPK	regulates	gene	0.65
AMPK	targets	gene	0.65
NRF2	associated_with	gene	0.50
BDNF	associated_with	gene	0.50
JNK	associated_with	gene	0.50
AUTOPHAGY	associated_with	phenotype	0.50
AMYLOID	associated_with	protein	0.50
ASTROCYTE	associated_with	cell_type	0.50
CREB	associated_with	gene	0.50
APP	associated_with	gene	0.45
GSK3B	associated_with	gene	0.45
AKT	associated_with	gene	0.45
CASP3	associated_with	gene	0.45
BCL2	associated_with	gene	0.45
BAX	associated_with	gene	0.45
CXCL10	associated_with	gene	0.45
GJA1	associated_with	gene	0.45
SEMAGLUTIDE	associated_with	drug	0.45
EXENATIDE	associated_with	drug	0.45
CORTEX	associated_with	brain_region	0.45
ALZHEIMER	associated_with	disease	0.45
ROS	associated_with	phenotype	0.45
METFORMIN	associated_with	drug	0.45
AMPK	associated_with	gene	0.45
APOPTOSIS	associated_with	phenotype	0.45
MAPK	associated_with	gene	0.45
SEMAGLUTIDE	metabolizes	drug	0.35

Incoming (14)

Source	Relation	Type	Str
BDNF	regulates	gene	0.70
ALZHEIMER'S DISEASE	produces	disease	0.60
CEREBRAL CORTEX	associated_with	brain_region	0.45
ALZHEIMER'S DISEASE	associated_with	disease	0.45
NEURODEGENERATION	associated_with	disease	0.45
MITOCHONDRIAL DYSFUNCTION	associated_with	phenotype	0.45
INSULIN SIGNALING	associated_with	pathway	0.45
NEUROINFLAMMATION	associated_with	phenotype	0.45
OXIDATIVE STRESS	associated_with	phenotype	0.45
INFLAMMATION	associated_with	phenotype	0.45
PARKINSON'S DISEASE	associated_with	disease	0.45
AMPK PATHWAY	associated_with	pathway	0.45
APP	inhibits	gene	0.35
CEREBRAL CORTEX	inhibits	brain_region	0.35

LIRAGLUTIDE

Understanding Entity Pages

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

PD Combination Therapy Matrix

nhp-validation-animal-model

PD Cure Roadmap

Outgoing (41)

Incoming (14)

Targeting Hypotheses (0)

Mentioning Analyses (0)

Related Papers (0)

LIRAGLUTIDE

Understanding Entity Pages

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

PD Combination Therapy Matrix

nhp-validation-animal-model

PD Cure Roadmap

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Clinical Trials Dashboard

Neuroprotection Strategies in Neurodegeneration

Insulin Signaling in Parkinson's Disease

Gut-Brain Axis in Neurodegeneration

glp1-receptor-agonists

Type 3 Diabetes Hypothesis of Alzheimer's Disease

Mitochondria in Neurodegeneration

NIH Drug Repurposing Program for Neurodegenerative Diseases

GLP-1 Signaling Pathway in Neurodegeneration

Arcuate Nucleus POMC Neurons

Energy Metabolism in Neurodegeneration

Zombosomes — Anucleated Cell Couriers in Alpha-Synuclein Propagation

Extracellular Vesicle-Mediated Synuclein Propagation Hypothesis in Parkinson's Disease

Therapeutic Modalities in Neurodegeneration

Outgoing (41)

Incoming (14)

Targeting Hypotheses (0)

Mentioning Analyses (0)

Related Papers (0)